000160930 001__ 160930
000160930 005__ 20180925134104.0
000160930 0247_ $$2doi$$a10.1038/ncponc1110
000160930 02470 $$2ISI$$a000256229200010
000160930 037__ $$aARTICLE
000160930 245__ $$aMechanisms of Disease: cancer stem cells - targeting the evil twin
000160930 269__ $$a2008
000160930 260__ $$c2008
000160930 336__ $$aReviews
000160930 520__ $$aClassical antineoplastic treatments such as chemotherapy or radiation can efficiently eradicate the majority of proliferating and genetically unstable malignant cells within neoplastic lesions. There is increasing evidence, however, that these regimens frequently fail to eliminate a minor subpopulation of resistant tumor cells that have distinct features of somatic stem cells. These serve as a reservoir for disease recurrence, and are the origin of metastatic growth. These so-called cancer stem cells (CSCs) or cancer-initiating cells represent often a rare, highly self-renewing population within the tumor mass, which is thought to be the only one required for both initiation and maintenance of disease. Tumor-cell populations enriched for CSC activity were originally identified in leukemias, but have now also been uncovered in a number of solid cancers. Their marked resistance towards classical antitumor regimens is mediated by the combination of several critical features, including relative dormancy, efficient DNA repair, high expression of multidrug-resistance-type membrane transporters and protection by a hypoxic niche environment. We review the concept of CSCs with particular emphasis on the mechanism of therapy resistance, and discuss potential future therapeutic interventions with the goal of specifically eliminating CSCs in a clinical setting.
000160930 6531_ $$acancer-initiating cell
000160930 6531_ $$achemotherapy
000160930 6531_ $$amultidrug resistance
000160930 6531_ $$aself-renewal
000160930 6531_ $$astem-cell niche
000160930 6531_ $$aAcute Myeloid-Leukemia
000160930 6531_ $$aAcute Lymphoblastic-Leukemia
000160930 6531_ $$aTumor-Initiating Cells
000160930 6531_ $$aBreast-Cancer
000160930 6531_ $$aIn-Vitro
000160930 6531_ $$aHematopoietic Stem
000160930 6531_ $$aSide Population
000160930 6531_ $$aProgenitor Cells
000160930 6531_ $$aCarcinoma-Cells
000160930 6531_ $$aDrug-Resistance
000160930 700__ $$0240661$$aTrumpp, Andreas$$g168677
000160930 700__ $$aWiestler, Otmar D.
000160930 773__ $$j5$$q337-347$$tNature Clinical Practice Oncology
000160930 909C0 $$0252368$$pUPTRU$$xU11160
000160930 909CO $$ooai:infoscience.tind.io:160930$$preview
000160930 917Z8 $$xWOS-2010-11-30
000160930 937__ $$aEPFL-REVIEW-160930
000160930 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000160930 980__ $$aREVIEW